Skip to content

Infinity Bio

3 viewers · 30d

Total raised

$2.0M

1 filing since 2025 · latest Debt filed

Cumulative raised
LAST ROUND
Debt · $2.0M
ROUNDS
1
INVESTORS
2
FOUNDED
2023
HQ
Baltimore, MD
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
3

AI overview

Updated

Infinity Bio, Inc. is an innovative biotechnology company focused on providing advanced antibody profiling services. Established in 2023 and headquartered in Baltimore, Maryland, the company utilizes cutting-edge technology developed at Johns Hopkins University to address the complexities of antibody responses within the immune system.

What sets it apart

Infinity Bio stands out by offering proprietary MIPSA technology, enabling detailed and comprehensive analyses of antibody reactivity across extensive antigen libraries.

Funding history

1 round
Debt+1Feb 18, 2025
Form D
+$2.0M$2.0M total

Latest SEC filings

via EDGAR · CIK 0001982572
Form D · Feb 18, 2025View on EDGAR

Products

1 tracked

MIPSA (Molecular Indexing of Proteins by Self-Assembly)

Antibody Profiling Technology

MIPSA is Infinity Bio's proprietary technology designed for the intricate mapping of antibody reactivity against large libraries of antigens. This innovative platform allows for comprehensive profiling of antibodies, facilitating a deeper understanding of immune responses.

  • Detailed antibody reactome profiling
  • Capability to analyze large antigen libraries
  • High-throughput analysis support
  • Support for custom antigen library creation

Links

WebsiteSEC EDGAR filings